ClinicalTrials.gg
CompletedNCT00524303Updated Nov 11, 2016Results posted

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

A Phase 2 interventional study of Trastuzumab and Paclitaxel in Neoplasms, Breast, sponsored by GlaxoSmithKline. Completed at 23 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-11.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

How we know · 10 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
125th of 366
100 · median 61
Started
2007
with 18 others
Phase 2
239 of 374
44 open now
Registered
104th of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 125th largest by enrollment of the 366 interventional ones that give a count, is one of 19 that started in 2007, is one of 239 in phase 2, and was the 104th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will examine safety and efficacy of Lapatinib in combination with a standard neoadjuvant chemotherapy including 5FU, Epirubicin, Cyclophosphamide and Paclitaxel. Tumor tissue will be obtained at 3 timepoints (optional 4th) to evaluate tumor response to treatment.

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • ErbB2 Overexpressing
  • ErbB2 Positive
  • Lapatinib
  • Invasive Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have signed an form (ICF) and a Patient Authorization Form (HIPAA).
  • Have or cytologically confirmed ErbB2- (/neu-) overexpressing invasive breast cancer (T2-4, N0-2).
  • ErbB2 overexpressing breast cancer, defined as one of the following definitions:
  • 3+ staining by immunohistochemistry (IHC),
  • a fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus
  • a FISH ratio of more than 2.2.
  • Have either measurable or evaluable disease.
  • Have an (ECOG) performance status (PS) of 0-1 (Refer to Section 11.4).
  • Have within the institutional range of normal as measured by either echocardiogram (ECHO) or MUGA scans. The same modality must be used consistently throughout the study.
  • Be deemed able to tolerate 8 cycles of preoperative chemotherapy, including 4 cycles with an anthracycline (epirubicin).
  • Must be willing to undergo 2 mandatory core (4 passes each) after diagnosis to obtain tissue for biologic expression profiling. Any subject with clinically palpable residual disease may undergo an optional third biopsy to allow identification of presumed pathways of resistance to therapy. This information might be useful in providing the subject with options for other targeted therapies if definitive surgery confirms residual disease. Definitive local therapy with surgery and radiation therapy as indicated will be performed after completion of 12 weeks of paclitaxel-based chemotherapy.
  • Are able to swallow and retain oral medication (intact pill).
  • Are able to complete all screening assessments as outlined in the protocol.
  • Have adequate organ function as defined in Table 4:

Table 1 Baseline Laboratory Values

Hematologic:

(absolute neutrophil count) >1.5 x 109/L >9 g/dL >75 x 109/L

Hepatic:

albumin >2.5 g/dL serum \<1.25 x / ALT \<3 x ULN if no documented liver AST / ALT \<3 x ULN with documented liver metastases

Renal:

serum creatinine \<2.0 mg/dL

  • OR - calculated >40 mL/min
  • Are subjects aged >18 years with any menopausal status:

Non- (i.e., women with functioning ovaries who have a current documented tubal ligation or hysterectomy, or women who are )

Child-bearing potential (i.e., women with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility.) This category includes women with oligomenorrhea (severe), women who are perimenopausal, and young women who have begun to menstruate. These subjects must have a negative serum pregnancy test at screening and agree to one of the following:

Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication; or Consistent and correct use of one of the following acceptable methods of : male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject; any intrauterine device (IUD) with a documented failure rate of less than 1% per year; oral contraceptives (either combined or progestogen only) where not for this subject population or per local practice.; or barrier methods, including diaphragm or condom with a spermicide.

Please note that breast cancer subjects on this trial cannot receive injectable levonorgestrel or injectable progestogen due to the potential for an adverse effect of anti-hormonal therapies on chemotherapy administered for breast cancer [Albain, 2002]. Progestogen may also affect the proliferative rate of endocrine-responsive tumors.

Exclusion criteria

Exclusion Criteria:

  • Have received any prior chemotherapy.
  • Had prior therapy with an ErbB1 and/or ErbB2 inhibitor.
  • Are receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, and biologic therapy) while taking study medication.
  • Have malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Women with ulcerative colitis are also excluded.
  • Have a concurrent disease or condition that would make the woman inappropriate for study participation, or any serious medical disorder that would interfere with the woman's safety.
  • Have an active or uncontrolled infection.
  • Have dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of .
  • Have active cardiac disease, defined as one or more of the following:

History of uncontrolled or symptomatic angina History of arrhythmias requiring medications, or Myocardial infarction \<6 months from study entry Uncontrolled or symptomatic congestive heart failure below the institutional normal limit Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient

  • Are pregnant or breastfeeding.
  • Have received concurrent treatment with an agent or participate in another clinical trial.
  • Have received concurrent treatment with prohibited medications (refer to Section 5.8.2 for details on prohibited medications).
  • Have used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.
  • Have a known immediate or delayed reaction or idiosyncrasy to drugs chemically related to any of the agents used in this study or their .
  • Are receiving therapeutic anti-coagulation therapy (i.e. warfarin, heparin).
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Trastuzumab alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles and Paclitaxel for 4 (21 day) cycles then continued trastuzumab until time of definitive surgery

    Drug: Trastuzumab · Drug: Paclitaxel · Drug: FEC75

  • Experimental
    Arm 2

    Lapatinib alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued lapatinib until time of definitive surgery

    Drug: Paclitaxel · Drug: FEC75 · Drug: Lapatinib

  • Experimental
    Arm 3

    Trastuzumab + Lapatinib for 2 weeks then added FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued trastuzumab + lapatinib until time of definitive surgery

    Drug: Trastuzumab · Drug: Paclitaxel · Drug: FEC75 · Drug: Lapatinib

Interventions

  • 4mg/kg IV loading dose followed by 2mg/kg IV weekly

  • 80mg/m2 IV weekly for 4 (21 day) cycles

  • DrugFEC75

    5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles

  • 1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy

    A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ \[DCIS\] or lobular carcinoma in situ \[LCIS\] was allowed). A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus). Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes. 26 weeks of therapy comprised the 2-week run-in phase, 12 weeks of treatment with FEC, and 12 weeks of treatment with Paclitaxel.

    Time frame: Week 26

Secondary outcomes

  1. Percentage of Participants With Clinical Complete Response (cCR) at 26 Weeks or at End of Treatment (EOT) or Early Withdrawal

    cCR was defined as the percentage of participants achieving either a Complete Response (CR) or a Partial Response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.

    Time frame: Week 26 or EOT or Early withdrawal

  2. Percentage of Participants (Par.) With Disease-free Survival (DFS) at the End of 5 Years From Randomization

    Percentage is the Kaplan Meier estimate of DFS. DFS is time from randomization until disease recurrence (contralateral breast cancer; second primary cancer; progression during neo-adjuvant treatment; or death from any cause). Par. who experienced progression during treatment and were withdrawn were considered to have a DFS event at withdrawal.

    Time frame: From first dose date until disease progression, assessed up to a maximum of 5 years

  3. Number of Participants With the Indicated Electrocardiogram (ECG) Status at Baseline and at EOT or Early Withdrawal

    12-lead ECGs were performed, and participants were classified as having normal ECG, abnormal- not clinically significant (NCS) ECG, and abnormal-clinically significant (CS) ECG per investigator opinion and reported result.

    Time frame: Baseline and EOT (up to Week 26) or Early withdrawal

  4. Cumulative Number of Participants With at Least One Decrease of More Than or Equal to 20% in Left Ventricular Ejection Fraction (LVEF) at the Indicated Time Points Compared to LVEF at Baseline

    LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction and is used to determine cardiac function. LVEF was measured by performing echocardiogram (ECHO). If ECHO could not be performed or if the investigator believed that it was not conclusive to evaluate LVEF, then a multigated acquisition (MUGA) scan was performed.

    Time frame: Weeks 3, 9, and 15; EOT or early withdrawal; and 3- and 6-month survival follow-up after last chemotherapy course

Other outcomes

  1. Mean Intra-tumoral Expression of the Indicated Proteins at Baseline and Day 14

    Expression (exp) of biomarker proteins (prot) were analyzed to determine if individual prot levels either in the Baseline or Day 14 breast tumor biopsy specimen correlated with breast pCR. A biomarker indicates a change in exp or state of a prot that correlates with the risk or disease progression, or with the susceptibility of the disease to a given treatment. Biomarkers are characteristic biological properties that can be detected and measured in parts of the body like blood or tissue. pCR=yes: participants (par.) had breast pCR. pCR=no: par. did not have breast pCR. Prot exp values are represented as normalized, scaled values; the unit of measurement is unit-less. Raw exp values were processed as follows: background subtraction of the raw exp value, then that value divided by beta-acting exp to normalize the exp value. A Standard Z score was calculated to scale the exp value.

    Time frame: Tumor core biopsy taken at Baseline and Treatment Day 14

  2. Cancer Stem Cells and the Correlation to Response/Non-response to Treatment

    Stem cell data were of poor quality and thus could not be analyzed. Increases or decreases in cancer stem cells and how the changes correlated with response/non-response to treatment were to have been assessed.

    Time frame: Tumor core biopsy taken at Baseline and Treatment Day 14

  3. Transcriptional Profiling of Total RNA and the Correlation to Response/Non-response to Treatment

    Transcriptional data were of poor quality and thus could not be analyzed. Gene pathways that correlate with response/non-response to treatment were to have been evaluated. The unit of measure is unit less; however, the processed values would be considered normalized relative expression level.

    Time frame: Tumor core biopsy taken at Baseline and Treatment Day 14

07

Results

Posted Aug 11, 2011

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumabLapatinibTrastuzumab+Lapatinib
Started333433
Completed212415
Not completed121018
Withdrew: Lost to follow-up603
Withdrew: Protocol violation011
Withdrew: Withdrawal by subject304
Withdrew: Death023
Withdrew: Adverse event123
Withdrew: Did not complete study dosing100
Withdrew: Worsening peripheral neuropathy100
Withdrew: Disease progression041
Withdrew: Disease recurrence010
Withdrew: Sponsor request001
Withdrew: Physician decision001
Withdrew: Completed 5 years001

Outcome measures

PrimaryPercentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy

A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ \[DCIS\] or lobular carcinoma in situ \[LCIS\] was allowed). A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus). Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes. 26 weeks of therapy comprised the 2-week run-in phase, 12 weeks of treatment with FEC, and 12 weeks of treatment with Paclitaxel.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy
percentage of participantsTrastuzumabLapatinibTrastuzumab+Lapatinib
Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy54.045.074.0
Statistical analysis
  • Trastuzumab vs Lapatinib · Percent difference: -9 · 95% CI -38.1 to 17.9Approximate 95% confidence interval for the difference in response rates between the trastuzumab arm and the lapatinib arm was calculated.
  • Trastuzumab vs Trastuzumab+Lapatinib · Percent difference: 20 · 95% CI -8.0 to 49.4Approximate 95% confidence interval for the difference in response rates between the transtuzumab arm and the transtuzumab + lapatinib arm was calculated.
SecondaryPercentage of Participants With Clinical Complete Response (cCR) at 26 Weeks or at End of Treatment (EOT) or Early Withdrawal

cCR was defined as the percentage of participants achieving either a Complete Response (CR) or a Partial Response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.

Time frame:
Week 26 or EOT or Early withdrawal
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Complete Response (cCR) at 26 Weeks or at End of Treatment (EOT) or Early Withdrawal
percentage of participantsTrastuzumabLapatinibTrastuzumab+Lapatinib
Percentage of Participants With Clinical Complete Response (cCR) at 26 Weeks or at End of Treatment (EOT) or Early Withdrawal61.068.061.0
Statistical analysis
  • Trastuzumab vs Lapatinib · Fisher Exact · p = 0.627 · Percent difference: 7 · 95% CI -17.8 to 32.5Approximate 95% confidence interval for the difference in response rates between the transtuzumab arm and the lapatinib arm was calculated.
  • Trastuzumab vs Trastuzumab+Lapatinib · Fisher Exact · p = 1.000 · Percent difference: 0 · 95% CI -25.1 to 25.1Approximate 95% confidence interval for the difference in response rates between the transtuzumab arm and the transtuzumab + lapatinib arm was calculated.
SecondaryPercentage of Participants (Par.) With Disease-free Survival (DFS) at the End of 5 Years From Randomization

Percentage is the Kaplan Meier estimate of DFS. DFS is time from randomization until disease recurrence (contralateral breast cancer; second primary cancer; progression during neo-adjuvant treatment; or death from any cause). Par. who experienced progression during treatment and were withdrawn were considered to have a DFS event at withdrawal.

Time frame:
From first dose date until disease progression, assessed up to a maximum of 5 years
Reported as:
Number · Percentage
Percentage of Participants (Par.) With Disease-free Survival (DFS) at the End of 5 Years From Randomization
PercentageTrastuzumabLapatinibTrastuzumab+Lapatinib
Percentage of Participants (Par.) With Disease-free Survival (DFS) at the End of 5 Years From Randomization90 (72 to 97)67 (47 to 80)66 (44 to 82)
SecondaryNumber of Participants With the Indicated Electrocardiogram (ECG) Status at Baseline and at EOT or Early Withdrawal

12-lead ECGs were performed, and participants were classified as having normal ECG, abnormal- not clinically significant (NCS) ECG, and abnormal-clinically significant (CS) ECG per investigator opinion and reported result.

Time frame:
Baseline and EOT (up to Week 26) or Early withdrawal
Reported as:
Number · participants
Number of Participants With the Indicated Electrocardiogram (ECG) Status at Baseline and at EOT or Early Withdrawal
participantsTrastuzumabLapatinibTrastuzumab+Lapatinib
Baseline, Normal, n= 28, 32, 30182323
Baseline, Abnormal-NCS, n= 28, 32, 301087
Baseline, Abnormal-CS, n= 28, 32, 30010
EOT/early withdrawal, Normal, n= 16, 21, 16101212
EOT/early withdrawal, Abnormal-NCS, n= 16, 21, 16684
EOT/early withdrawal, Abnormal-CS, n= 16, 21, 16010
SecondaryCumulative Number of Participants With at Least One Decrease of More Than or Equal to 20% in Left Ventricular Ejection Fraction (LVEF) at the Indicated Time Points Compared to LVEF at Baseline

LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction and is used to determine cardiac function. LVEF was measured by performing echocardiogram (ECHO). If ECHO could not be performed or if the investigator believed that it was not conclusive to evaluate LVEF, then a multigated acquisition (MUGA) scan was performed.

Time frame:
Weeks 3, 9, and 15; EOT or early withdrawal; and 3- and 6-month survival follow-up after last chemotherapy course
Reported as:
Number · participants
Cumulative Number of Participants With at Least One Decrease of More Than or Equal to 20% in Left Ventricular Ejection Fraction (LVEF) at the Indicated Time Points Compared to LVEF at Baseline
participantsTrastuzumabLapatinibTrastuzumab+Lapatinib
Week 3, n= 30, 31, 26101
Week 9, n= 30, 32, 27101
Week 15, n= 31, 34, 28122
Early withdrawal/EOT, n= 31, 34, 28142
3-month survival follow-up, n= 31, 34, 28243
6-month survival follow-up, n= 31, 34, 28444
Other pre-specifiedMean Intra-tumoral Expression of the Indicated Proteins at Baseline and Day 14

Expression (exp) of biomarker proteins (prot) were analyzed to determine if individual prot levels either in the Baseline or Day 14 breast tumor biopsy specimen correlated with breast pCR. A biomarker indicates a change in exp or state of a prot that correlates with the risk or disease progression, or with the susceptibility of the disease to a given treatment. Biomarkers are characteristic biological properties that can be detected and measured in parts of the body like blood or tissue. pCR=yes: participants (par.) had breast pCR. pCR=no: par. did not have breast pCR. Prot exp values are represented as normalized, scaled values; the unit of measurement is unit-less. Raw exp values were processed as follows: background subtraction of the raw exp value, then that value divided by beta-acting exp to normalize the exp value. A Standard Z score was calculated to scale the exp value.

Time frame:
Tumor core biopsy taken at Baseline and Treatment Day 14
Reported as:
Mean · : normalized relative expression level
Mean Intra-tumoral Expression of the Indicated Proteins at Baseline and Day 14
: normalized relative expression levelTrastuzumabLapatinib
Baseline, EGFR_Tyr1068; pCR=yes, n=0, 4NA ± NA-0.70 ± 0.47
Baseline, Baseline, EGFR_Tyr1068; pCR=no, n=0, 11NA ± NA0.05 ± 0.55
Post Baseline, EGFR_Tyr1068; pCR=yes, n=9, 00.65 ± 1.02NA ± NA
Post Baseline, EGFR_Tyr1068; pCR=no, n=6, 0-0.26 ± 0.56NA ± NA
Day 14, pSTAT5; pCR=yes, n=11, 6NA ± NANA ± NA
Day 14, pSTAT5; pCR=no, n=9, 11NA ± NANA ± NA
Post Baseline, PI3K; pCR=yes, n=0, 5NA ± NA0.46 ± 0.73
Post Baseline, PI3K; pCR=no, n=0, 10NA ± NA-0.53 ± 0.67
Post Baseline, LC3B; pCR=yes, n=0, 5NA ± NA0.68 ± 0.81
Post Baseline, LC3B; pCR=no, n=0, 10NA ± NA-0.43 ± 0.75
Post Baseline, MMP9; pCR=yes, n=0, 5NA ± NA0.71 ± 0.34
Post Baseline, MMP9; pCR=no, n=0, 5NA ± NA-0.48 ± 0.48
Post Baseline, GSK3_a_b_Tyr279_216; pCR=yes, n=8,00.26 ± 0.82NA ± NA
Post Baseline, GSK3_a_b_Tyr279_216; pCR=no, n=5,0-0.86 ± 0.67NA ± NA
Other pre-specifiedCancer Stem Cells and the Correlation to Response/Non-response to Treatment

Stem cell data were of poor quality and thus could not be analyzed. Increases or decreases in cancer stem cells and how the changes correlated with response/non-response to treatment were to have been assessed.

Time frame:
Tumor core biopsy taken at Baseline and Treatment Day 14

No measurements were reported for this outcome.

Other pre-specifiedTranscriptional Profiling of Total RNA and the Correlation to Response/Non-response to Treatment

Transcriptional data were of poor quality and thus could not be analyzed. Gene pathways that correlate with response/non-response to treatment were to have been evaluated. The unit of measure is unit less; however, the processed values would be considered normalized relative expression level.

Time frame:
Tumor core biopsy taken at Baseline and Treatment Day 14

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab—7/32 (21.9%)31/32 (96.9%)
Lapatinib—7/34 (20.6%)34/34 (100%)
Trastuzumab+Lapatinib—8/31 (25.8%)31/31 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventTrastuzumabLapatinibTrastuzumab+Lapatinib
Febrile nuetropeniaBlood and lymphatic system disorders3/320/342/31
NeutropeniaBlood and lymphatic system disorders3/320/341/31
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/320/341/31
PyrexiaGeneral disorders0/323/340/31
DiarrhoeaGastrointestinal disorders0/322/342/31
GastroenteritisInfections and infestations0/320/341/31
Urinary tract infectionInfections and infestations0/320/341/31
VomitingGastrointestinal disorders0/321/341/31
NauseaGastrointestinal disorders0/320/341/31
StomatitisGastrointestinal disorders0/320/341/31
Most frequent other events
Showing 10 of 118
Most frequent other events
EventTrastuzumabLapatinibTrastuzumab+Lapatinib
DiarrhoeaGastrointestinal disorders17/3229/3431/31
NauseaGastrointestinal disorders26/3226/3426/31
RashSkin and subcutaneous tissue disorders14/3228/3426/31
FatigueGeneral disorders22/3224/3424/31
AlopeciaSkin and subcutaneous tissue disorders21/3224/3418/31
Neuropathy peripheralNervous system disorders15/3219/3414/31
NeutropeniaBlood and lymphatic system disorders13/3212/3415/31
VomitingGastrointestinal disorders7/3215/348/31
AnemiaBlood and lymphatic system disorders10/3212/3412/31
ConstipationGastrointestinal disorders12/328/346/31

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TrastuzumabLapatinibTrastuzumab+LapatinibTotal
Mean51.1 ± 10.9050.8 ± 8.7649.2 ± 10.4750.4 ± 10.01
Sex: Female, Male
Sex: Female, Male(Participants)TrastuzumabLapatinibTrastuzumab+LapatinibTotal
Female333433100
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)TrastuzumabLapatinibTrastuzumab+LapatinibTotal
African American/African heritage81211
American Indian or Alaska native0011
Asian - Central/South Asian heritage0101
Asian - East Asian heritage0101
Asian - South East Asian heritage0213
White - Arabic/North African heritage0101
White - White/Caucasian/European heritage25272981
Mixed race0101
08

Study locations

23 sites
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Los Angeles, California 90057, United States
  • GSK Investigational Site
    Denver, Colorado 80220, United States
  • GSK Investigational Site
    Hudson, Florida 34667, United States
  • GSK Investigational Site
    Miami, Florida 33176, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33028, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46219, United States
  • GSK Investigational Site
    Henderson, Nevada 89052, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Austin, Texas 78731, United States
  • GSK Investigational Site
    Beaumont, Texas 77702-1449, United States
  • GSK Investigational Site
    Bedford, Texas 76022, United States
  • GSK Investigational Site
    Dallas, Texas 75231, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Dallas, Texas 75320-2510, United States
  • GSK Investigational Site
    El Paso, Texas 79915, United States
  • GSK Investigational Site
    Houston, Texas 77024, United States
  • GSK Investigational Site
    Lewisville, Texas 75067, United States
  • GSK Investigational Site
    Sugar Land, Texas 77479, United States
  • GSK Investigational Site
    Tyler, Texas 75702, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Seattle, Washington 98117, United States
  • GSK Investigational Site
    Yakima, Washington 98902, United States
09

References and documents

Publications

  • O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17. PubMed 29156708 ↗
  • Holmes FA, Espina V, Liotta LA, Nagarwala YM, Danso M, McIntyre KJ, Osborne CR, Anderson T, Krekow L, Blum JL, Pippen J, Florance A, Mahoney J, O'Shaughnessy JA. Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Res Notes. 2013 Dec 5;6:507. doi: 10.1186/1756-0500-6-507. PubMed 24304724 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Oct 2010 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2007
First posted
Sep 3, 2007
Start
Aug 2007
Primary completionActual
Oct 2010
CompletionActual
Aug 2015
Results first posted
Aug 11, 2011
Last update
Nov 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00524303
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 3, 2007
Start date
Aug 2007
Primary completion
Oct 2010
Completion
Aug 2015
Results posted
Aug 11, 2011
Last update
Nov 11, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion